Literature DB >> 26078391

Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.

Ming-Hsien Chien1, Wei-Jiunn Lee2, Feng-Koo Hsieh3, Chia-Feng Li4, Tsu-Yao Cheng5, Ming-Yang Wang6, Jin-Shing Chen6, Jyh-Ming Chow7, Yi-Hua Jan8, Michael Hsiao8, Kuo-Tai Hua9, Min-Liang Kuo10.   

Abstract

PURPOSE: Kelch-like ECH-associated protein 1 (Keap1) is an E3 ligase participated in the cellular defense response against oxidative stress through nuclear factor erythroid-2-related factor 2 (Nrf2). However, the role of Keap1 in regulating cancer motility is still controversial. We investigated the contribution of the Keap1-Nrf2 axis in the progression of non-small cell lung cancer (NSCLC). EXPERIMENTAL
DESIGN: The expression of Keap1 and Nrf2 was examined via immunohistochemistry, real-time PCR, and Western blot analysis in a cohort of NSCLC tissues and cells. A series of in vivo and in vitro assays was performed to elucidate the contribution of the Keap1-Nrf2 axis in lung cancer mobility and progression.
RESULTS: Keap1 expression was decreased in specimens from NSCLC patients with lymph node metastasis compared with patients without metastasis. Higher Keap1 expression levels were correlated with the survival of NSCLC patients. Moreover, manipulation of Keap1 expression affected cell migration/invasion abilities. Depletion of Nrf2 relieved the migration promotion imposed by Keap1 suppression. Mechanistic investigations found that S100P was downregulated in both Keap1-overexpressing and Nrf2-knockdown NSCLC cells. Overexpression of Keap1 and knockdown of Nrf2 both suppressed S100P expression in NSCLC cells. Knockdown of S100P inhibited cell migration in highly invasive NSCLC cells and also relieved the migration promotion imposed by Keap1 suppression in weakly invasive NSCLC cells.
CONCLUSIONS: Our findings suggest that Keap1 functions as a suppressor of tumor metastasis by targeting the Nrf2/S100P pathway in NSCLC cells. In addition, overexpression of Keap1 may be a novel NSCLC treatment strategy and/or useful biomarker for predicting NSCLC progression. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26078391     DOI: 10.1158/1078-0432.CCR-14-2880

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.

Authors:  Shunhao Zhang; Sining Duan; Zhuojun Xie; Wanlin Bao; Bo Xu; Wenbin Yang; Lingyun Zhou
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

2.  Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma.

Authors:  Yongxing Zhang; Hong Fan; Shuo Fang; Lin Wang; Li Chen; Yulin Jin; Wei Jiang; Zongwu Lin; Yu Shi; Cheng Zhan; Qun Wang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Systematic analysis of mRNA expression profiles in NSCLC cell lines to screen metastasis-related genes.

Authors:  Ying Liu; Lei Liu; Tao Yu; He-Chun Lin; Dandan Chu; Wei Deng; Ming-Xia Yan; Jing Li; Ming Yao
Journal:  Mol Med Rep       Date:  2016-11-01       Impact factor: 2.952

4.  Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer.

Authors:  Yung-Wei Lin; Yu-Ching Wen; Chih-Ying Chu; Min-Che Tung; Yi-Chieh Yang; Kuo-Tai Hua; Ke-Fan Pan; Michael Hsiao; Wei-Jiunn Lee; Ming-Hsien Chien
Journal:  Cell Death Dis       Date:  2020-07-27       Impact factor: 8.469

5.  Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells.

Authors:  Agnieszka Gęgotek; Jacek Nikliński; Neven Žarković; Kamelija Žarković; Georg Waeg; Wojciech Łuczaj; Radosław Charkiewicz; Elżbieta Skrzydlewska
Journal:  Redox Biol       Date:  2016-08-20       Impact factor: 11.799

6.  Predicting Diagnostic Gene Biomarkers for Non-Small-Cell Lung Cancer.

Authors:  Bin Liang; Yang Shao; Fei Long; Shu-Juan Jiang
Journal:  Biomed Res Int       Date:  2016-07-31       Impact factor: 3.411

7.  Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.

Authors:  Jiang Chen; Yaojun Yu; Tong Ji; Rui Ma; Mingming Chen; Gaofeng Li; Feibo Li; Qiong Ding; Qingsong Kang; Diyu Huang; Xiao Liang; Hui Lin; Xiujun Cai
Journal:  Cancer Med       Date:  2016-09-20       Impact factor: 4.452

Review 8.  Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.

Authors:  F P Fabrizio; A Sparaneo; D Trombetta; L A Muscarella
Journal:  Oxid Med Cell Longev       Date:  2018-03-13       Impact factor: 6.543

9.  PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2.

Authors:  Ya-Min Cheng; Po-Lin Lin; De-Wei Wu; Lee Wang; Chi-Chou Huang; Huei Lee
Journal:  Oncotarget       Date:  2018-05-29

10.  A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.

Authors:  Olivia Adams; Félice A Janser; Bastian Dislich; Sabina Berezowska; Magali Humbert; Christian A Seiler; Dino Kroell; Julia Slotta-Huspenina; Marcus Feith; Katja Ott; Mario P Tschan; Rupert Langer
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.